Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical ...

Five years from the start of the COVID-19 pandemic, numerous academic studies have shown how the novel coronavirus affects ocular health.

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations ...

Researchers at Umeå University have discovered that the SARS-CoV-2 variant omicron has developed a stronger binding to human ...

As scientists, we often think we understand a virus—its structure, its tricks, the way it moves through the body. But every ...

New research reveals that severe COVID-19 pneumonia can cause lasting lung damage, primarily due to impaired pulmonary capillary function rather than alveolar membrane damage.

Key findings • Sarcoidosis patients are prone to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, increased severity, morbidity and greater mortality of coronavirus disease 2019 ...

the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells in the lungs remain elusive. Here we conducted integrated single-cell profiling of SARS-CoV-2 ...

(AP Photo/Alessandra Tarantino, File) ROME (AP) — Pope Francis will be released from hospital on Sunday after 38 days battling a severe case of pneumonia in both lungs that threatened his life on two ...

ROME (AP) — Pope Francis will be released from the hospital on Sunday, after 38 days battling a life-threatening case of pneumonia in both lungs, his doctors said. Gemelli medical director Dr ...